This document discusses orphan diseases, orphan drugs, and regulatory aspects of orphan drugs in the US and Europe. It defines orphan diseases as those affecting fewer than 200,000 people in the US or 1 in 2000 people in Europe. Despite affecting a small percentage of the population, over 55 million people in the US and EU have orphan diseases. The document outlines regulations in the US and EU to incentivize development of orphan drugs, including market exclusivity periods. Key incentives include clinical trial cost subsidies and expedited FDA review in the US, as well as free orphan designation review by the EMA in Europe.
The orphan drug area is relatively new but fast growing. Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
Orphan drugs are intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the US or 5 in 10,000 people in the EU. Various acts like the Orphan Drug Act of 1983 in the US and the Rare Diseases Act of 2002 in the EU provide incentives like market exclusivity periods of 7-10 years and waivers on fees for drug approval to encourage development of treatments for rare diseases. However, developing orphan drugs remains challenging due to the small patient populations and high costs. Major pharmaceutical companies and some specialist companies are involved in orphan drug development and access to these treatments remains a priority.
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
The Office of Orphan Products Development (OOPD) at the FDA promotes the development of treatments for rare diseases and conditions. There are more than 6,800 known rare diseases affecting an estimated 25-30 million Americans. The Orphan Drug Act of 1983 provides financial incentives like tax credits, user fee waivers, and exclusive marketing rights for 7 years to encourage development of treatments for rare diseases. The OOPD oversees programs that grant orphan drug designation, provide funding for clinical trials and natural history studies, and award priority review vouchers for rare pediatric diseases.
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Michael Swit
Webinar sponsored by The Weinberg Group on Orphan Drugs, covering these topics:
The Basics of the Orphan Drug Act
Benefits of Orphan Drug status
Exclusivity
Protocol assistance, tax credits, and research grants
When is an indication is “rare”?
Orphan Drug Designation Requests – ensuring yours
robust and persuasive
Approval criteria for orphan products – how they
compare to non-orphan products
Challenges in the Orphan Drug Process
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
The orphan drug area is relatively new but fast growing. Over the next weeks, Black Swan Consulting will summarise information on this class of drug products. Please also see http://black-swan-consulting.com/what-is-cooking/Orphan-drugs.
Orphan drugs are intended for the treatment of rare diseases or conditions affecting fewer than 200,000 people in the US or 5 in 10,000 people in the EU. Various acts like the Orphan Drug Act of 1983 in the US and the Rare Diseases Act of 2002 in the EU provide incentives like market exclusivity periods of 7-10 years and waivers on fees for drug approval to encourage development of treatments for rare diseases. However, developing orphan drugs remains challenging due to the small patient populations and high costs. Major pharmaceutical companies and some specialist companies are involved in orphan drug development and access to these treatments remains a priority.
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
The Office of Orphan Products Development (OOPD) at the FDA promotes the development of treatments for rare diseases and conditions. There are more than 6,800 known rare diseases affecting an estimated 25-30 million Americans. The Orphan Drug Act of 1983 provides financial incentives like tax credits, user fee waivers, and exclusive marketing rights for 7 years to encourage development of treatments for rare diseases. The OOPD oversees programs that grant orphan drug designation, provide funding for clinical trials and natural history studies, and award priority review vouchers for rare pediatric diseases.
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Michael Swit
Webinar sponsored by The Weinberg Group on Orphan Drugs, covering these topics:
The Basics of the Orphan Drug Act
Benefits of Orphan Drug status
Exclusivity
Protocol assistance, tax credits, and research grants
When is an indication is “rare”?
Orphan Drug Designation Requests – ensuring yours
robust and persuasive
Approval criteria for orphan products – how they
compare to non-orphan products
Challenges in the Orphan Drug Process
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
The document discusses generic drugs, including their regulatory approval process. Generic drugs must demonstrate bioequivalence to the branded version to gain approval. They are approved through an abbreviated new drug application that shows they deliver the same amount of active ingredients as the branded drug. India has a large and growing generic drug industry that supplies over 30% of the global generic market. Recent FDA rules now require generic drug makers to pay user fees for product approvals.
Regulatory aspects of orphan drugs devolpmentsJITHIN K JOY
This document discusses regulatory aspects of orphan drugs and developments. It begins by defining orphan diseases and the need for orphan drug regulation to incentivize development of treatments for rare conditions. It describes orphan drug regulations in various countries like the US, Japan, Australia and challenges in developing orphan drugs. In India, around 6000-8000 rare diseases have been identified but many lack treatments. The document calls for India to introduce its own orphan drug act to define rare diseases, provide incentives for research and improve access to existing orphan drugs.
The document discusses orphan drugs and regulations around them in various markets. It provides an overview of orphan drug policies in the US, EU, Australia, and Canada. The US Orphan Drug Act of 1983 was the first legislation to promote orphan drug development. It offers 7 years of market exclusivity. The EU and Canada have since established their own orphan drug frameworks that similarly aim to incentivize development of treatments for rare diseases through exclusivity periods, fee waivers, and assistance programs. However, orphan drugs regulations still face challenges around definitions of rare diseases, clinical data requirements, pricing and reimbursement.
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN Arul Packiadhas
The document provides an overview of drug regulatory agencies in India, the US, Europe, and Japan. It discusses the common functions of drug regulation including ensuring drug safety, licensing, inspections, and adverse event monitoring. For each region, it outlines the key regulatory bodies and their responsibilities. In India, the main agencies are CDSCO, NIHFW, DTAB, ICMR, and CDTL. In the US, the FDA oversees drug approval and safety. The key European agencies are EDQM and EMA, while Japan's PMDA regulates pharmaceuticals.
Regulatory requirements for otc drugs as per usfdaKhushboo Bhatia
Over-the-counter (OTC) drugs are medicines that can be sold directly to consumers without a prescription. In the US, the FDA regulates OTC drugs to ensure they are safe and effective for use without medical supervision. The FDA approves OTC drugs either through the OTC monograph system, which regulates well-established ingredients by therapeutic class, or through the new drug application process for products that do not fit existing monographs. Regulations cover manufacturing, clinical testing, facility registration, importation, safety monitoring, and risk management for both OTC and prescription drugs.
The document compares the drug approval processes in the US and India. In the US, the process involves an Investigational New Drug (IND) application to begin clinical trials, followed by a New Drug Application (NDA) if clinical studies show the drug is safe and effective. In India, companies must apply for permission by submitting data to the Drugs Controller General of India and conduct clinical trials according to guidelines. Both countries have stringent approval standards aimed at safeguarding public health by ensuring drugs are properly tested and manufactured.
Regulatory requirements for orphan drugs delivery, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgavi/Belgaum, Karnataka, India.
Over-the-counter (OTC) drugs are medications that can be safely used without a prescription. In the US, the FDA regulates OTC drugs to ensure they are safe and effective for self-treatment of common health issues. The FDA reviews OTC products and establishes labeling regulations. There are two pathways for legal OTC drug marketing: compliance with an OTC drug monograph or approval under a new drug application. OTC drugs are generally low risk for abuse and allow for wider access and treatment of minor conditions. Proper labeling, safety, efficacy, and manufacturing standards are required of all OTC drugs.
This document summarizes the regulations and history around generic drug applications (ANDAs) in the United States. It explains that an ANDA is an application to produce a generic version of an approved drug that is the same in dosage, strength, and use. The document outlines the basic requirements for generic drugs and discusses the historical approval pathways including ANDAs, paper NDAs, and monographs that preceded the modern system established by the Hatch-Waxman Act of 1984. This law standardized the ANDA process and established provisions to balance generic competition with patent protections for brand drugs.
This document provides an overview of regulatory affairs for drugs. It defines key terms like regulatory affairs, dossier, CTD, eCTD, DMF, NDA, ANDA, and INDA. It describes the role of regulatory affairs experts in guiding product development according to regulatory requirements, compiling dossiers for submission, and ensuring post-marketing compliance. The document outlines a 10 step process for regulatory product development and regulatory submission preparation. It also discusses quality management systems for regulatory compliance and the role of regulatory affairs in marketing and advertising compliance.
The document discusses the organization of the US Food and Drug Administration (FDA). It describes that the FDA regulates food, drugs, medical devices, cosmetics, and tobacco. It is organized into six product centers that regulate specific areas, a research center, and two offices. The centers regulate drugs, biologics, devices, food, veterinary medicine, and tobacco. The Office of Regulatory Affairs conducts inspections and investigations. The Office of the Commissioner provides leadership. Employment in 2013 totaled 14,589 across the various centers and offices.
The document is a presentation about orphan drugs given by Dr. Atul Rajpara. It defines orphan drugs as those intended for the treatment of rare diseases or disorders. It discusses how rare diseases are defined in various countries and notes that over 7,000 rare diseases have been identified worldwide. The presentation outlines the Orphan Drug Act of 1983 in the US and its impact in incentivizing orphan drug development. It also discusses the orphan drug designation process and provides some examples of orphan drugs and their manufacturers. The presentation concludes by noting challenges to improving access to orphan drugs in India like affordability and a lack of incentives for drug developers.
This document discusses orphan drugs, which treat rare diseases. It defines orphan drugs and outlines criteria used in the US and EU to designate drugs for rare diseases. Rare diseases affect fewer than 200,000 people in the US and 10,000 in the EU. The Orphan Drug Act of 1983 in the US provided incentives for orphan drug development. Similar laws exist in other countries. Developing orphan drugs is challenging due to low patient populations and high costs. Examples of orphan drugs and their manufacturers are provided. The process for obtaining orphan drug designation is also summarized.
Systems of documentation and record keeping in clinical pharmacyKenneth Bitrus David
This document discusses systems of documentation and record keeping in clinical pharmacy. It outlines several types of documentation styles used in clinical pharmacy including unstructured notes, semi-structured notes, and systematic records. Common record types include patient records, inventory records, administrative records, and financial records. Systems like SOAP (subjective, objective, assessment, plan) and TITRS (title, introduction, text, recommendation, signature) notes are described. The importance of documentation, legal considerations, and examples of documentation forms are also covered.
An overveiw on regulation of otc drug product in different countryNitin Patel
This document discusses over-the-counter (OTC) drugs and regulations regarding OTC drugs in India, the United States, and Europe. It defines OTC drugs as drugs that can be purchased without a prescription and are considered safe for self-treatment. The key points covered include: OTC drug schedules in India, examples of common OTC drugs, regulations governing labeling, advertising and distribution of OTC drugs in each region, and processes for switching a drug from prescription to OTC status. Comparisons are made between the regulatory approaches in different jurisdictions.
The regulation of complementary medicinesTGA Australia
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Rare Diseases: A Report on Orphan Drugs in the PipelinePhRMA
Rare diseases, when taken together, are not that rare at all. In fact, according to the National Institutes of Health (NIH), 30 million Americans have one of the nearly 7,000 diseases that are officially deemed “rare” because alone they each affect fewer than 200,000 people in the United States.
The document discusses generic drugs, including their regulatory approval process. Generic drugs must demonstrate bioequivalence to the branded version to gain approval. They are approved through an abbreviated new drug application that shows they deliver the same amount of active ingredients as the branded drug. India has a large and growing generic drug industry that supplies over 30% of the global generic market. Recent FDA rules now require generic drug makers to pay user fees for product approvals.
Regulatory aspects of orphan drugs devolpmentsJITHIN K JOY
This document discusses regulatory aspects of orphan drugs and developments. It begins by defining orphan diseases and the need for orphan drug regulation to incentivize development of treatments for rare conditions. It describes orphan drug regulations in various countries like the US, Japan, Australia and challenges in developing orphan drugs. In India, around 6000-8000 rare diseases have been identified but many lack treatments. The document calls for India to introduce its own orphan drug act to define rare diseases, provide incentives for research and improve access to existing orphan drugs.
The document discusses orphan drugs and regulations around them in various markets. It provides an overview of orphan drug policies in the US, EU, Australia, and Canada. The US Orphan Drug Act of 1983 was the first legislation to promote orphan drug development. It offers 7 years of market exclusivity. The EU and Canada have since established their own orphan drug frameworks that similarly aim to incentivize development of treatments for rare diseases through exclusivity periods, fee waivers, and assistance programs. However, orphan drugs regulations still face challenges around definitions of rare diseases, clinical data requirements, pricing and reimbursement.
OVERVIEW OF DRUG REGULATORY AGENCIES IN INDIA, USA, EUROPE AND JAPAN Arul Packiadhas
The document provides an overview of drug regulatory agencies in India, the US, Europe, and Japan. It discusses the common functions of drug regulation including ensuring drug safety, licensing, inspections, and adverse event monitoring. For each region, it outlines the key regulatory bodies and their responsibilities. In India, the main agencies are CDSCO, NIHFW, DTAB, ICMR, and CDTL. In the US, the FDA oversees drug approval and safety. The key European agencies are EDQM and EMA, while Japan's PMDA regulates pharmaceuticals.
Regulatory requirements for otc drugs as per usfdaKhushboo Bhatia
Over-the-counter (OTC) drugs are medicines that can be sold directly to consumers without a prescription. In the US, the FDA regulates OTC drugs to ensure they are safe and effective for use without medical supervision. The FDA approves OTC drugs either through the OTC monograph system, which regulates well-established ingredients by therapeutic class, or through the new drug application process for products that do not fit existing monographs. Regulations cover manufacturing, clinical testing, facility registration, importation, safety monitoring, and risk management for both OTC and prescription drugs.
The document compares the drug approval processes in the US and India. In the US, the process involves an Investigational New Drug (IND) application to begin clinical trials, followed by a New Drug Application (NDA) if clinical studies show the drug is safe and effective. In India, companies must apply for permission by submitting data to the Drugs Controller General of India and conduct clinical trials according to guidelines. Both countries have stringent approval standards aimed at safeguarding public health by ensuring drugs are properly tested and manufactured.
Regulatory requirements for orphan drugs delivery, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgavi/Belgaum, Karnataka, India.
Over-the-counter (OTC) drugs are medications that can be safely used without a prescription. In the US, the FDA regulates OTC drugs to ensure they are safe and effective for self-treatment of common health issues. The FDA reviews OTC products and establishes labeling regulations. There are two pathways for legal OTC drug marketing: compliance with an OTC drug monograph or approval under a new drug application. OTC drugs are generally low risk for abuse and allow for wider access and treatment of minor conditions. Proper labeling, safety, efficacy, and manufacturing standards are required of all OTC drugs.
This document summarizes the regulations and history around generic drug applications (ANDAs) in the United States. It explains that an ANDA is an application to produce a generic version of an approved drug that is the same in dosage, strength, and use. The document outlines the basic requirements for generic drugs and discusses the historical approval pathways including ANDAs, paper NDAs, and monographs that preceded the modern system established by the Hatch-Waxman Act of 1984. This law standardized the ANDA process and established provisions to balance generic competition with patent protections for brand drugs.
This document provides an overview of regulatory affairs for drugs. It defines key terms like regulatory affairs, dossier, CTD, eCTD, DMF, NDA, ANDA, and INDA. It describes the role of regulatory affairs experts in guiding product development according to regulatory requirements, compiling dossiers for submission, and ensuring post-marketing compliance. The document outlines a 10 step process for regulatory product development and regulatory submission preparation. It also discusses quality management systems for regulatory compliance and the role of regulatory affairs in marketing and advertising compliance.
The document discusses the organization of the US Food and Drug Administration (FDA). It describes that the FDA regulates food, drugs, medical devices, cosmetics, and tobacco. It is organized into six product centers that regulate specific areas, a research center, and two offices. The centers regulate drugs, biologics, devices, food, veterinary medicine, and tobacco. The Office of Regulatory Affairs conducts inspections and investigations. The Office of the Commissioner provides leadership. Employment in 2013 totaled 14,589 across the various centers and offices.
The document is a presentation about orphan drugs given by Dr. Atul Rajpara. It defines orphan drugs as those intended for the treatment of rare diseases or disorders. It discusses how rare diseases are defined in various countries and notes that over 7,000 rare diseases have been identified worldwide. The presentation outlines the Orphan Drug Act of 1983 in the US and its impact in incentivizing orphan drug development. It also discusses the orphan drug designation process and provides some examples of orphan drugs and their manufacturers. The presentation concludes by noting challenges to improving access to orphan drugs in India like affordability and a lack of incentives for drug developers.
This document discusses orphan drugs, which treat rare diseases. It defines orphan drugs and outlines criteria used in the US and EU to designate drugs for rare diseases. Rare diseases affect fewer than 200,000 people in the US and 10,000 in the EU. The Orphan Drug Act of 1983 in the US provided incentives for orphan drug development. Similar laws exist in other countries. Developing orphan drugs is challenging due to low patient populations and high costs. Examples of orphan drugs and their manufacturers are provided. The process for obtaining orphan drug designation is also summarized.
Systems of documentation and record keeping in clinical pharmacyKenneth Bitrus David
This document discusses systems of documentation and record keeping in clinical pharmacy. It outlines several types of documentation styles used in clinical pharmacy including unstructured notes, semi-structured notes, and systematic records. Common record types include patient records, inventory records, administrative records, and financial records. Systems like SOAP (subjective, objective, assessment, plan) and TITRS (title, introduction, text, recommendation, signature) notes are described. The importance of documentation, legal considerations, and examples of documentation forms are also covered.
An overveiw on regulation of otc drug product in different countryNitin Patel
This document discusses over-the-counter (OTC) drugs and regulations regarding OTC drugs in India, the United States, and Europe. It defines OTC drugs as drugs that can be purchased without a prescription and are considered safe for self-treatment. The key points covered include: OTC drug schedules in India, examples of common OTC drugs, regulations governing labeling, advertising and distribution of OTC drugs in each region, and processes for switching a drug from prescription to OTC status. Comparisons are made between the regulatory approaches in different jurisdictions.
The regulation of complementary medicinesTGA Australia
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
breif notes on what is pharmacoepidemiology, why do we need pharmacoepidemiology, whats is its aim and its main applications, advantages and disadvantages
Rare Diseases: A Report on Orphan Drugs in the PipelinePhRMA
Rare diseases, when taken together, are not that rare at all. In fact, according to the National Institutes of Health (NIH), 30 million Americans have one of the nearly 7,000 diseases that are officially deemed “rare” because alone they each affect fewer than 200,000 people in the United States.
ROJoson PEP Talk: Rare, Uncommon and Common DiseasesReynaldo Joson
This document summarizes a presentation on rare, uncommon, and common diseases. The presentation discusses the definitions and statistics around rare diseases, provides examples like Maple Syrup Urine Disease, and explores the challenges of diagnosing and treating rare diseases. It also explains the differences between rare, uncommon and common diseases, noting that rare diseases occur in less than 1 in 20,000 people in the Philippines. The presentation aims to empower laypeople to better understand these disease classifications and manage their own healthcare.
This document summarizes a seminar presentation on orphan drug designations and approvals. It begins with introducing rare diseases and defining orphan drugs. It then discusses the key aspects of the Orphan Drug Act of 1983 in the US that provides incentives for orphan drug development, including 7 years of market exclusivity. The document outlines the orphan drug designation process through the FDA, including the application process. It also summarizes the incentives provided through the Act, such as tax credits, grants, and fee waivers, to encourage pharmaceutical companies to develop treatments for rare diseases.
Enfermedad minoritaria, terapias nuevas. Una patología que afecta a menos de cinco personas por cada 10.000 habitantes es considerada una enfermedad rara o minoritaria. 35 millones de europeos se ven afectados por alguna de ellas. El 80% son de origen genético y conseguir un diagnóstico rápido es vital para asegurar la calidad de vida futura. La clave, una vez más, es apostar y potenciar la investigación biomédica. Se revisarán los resultados obtenidos los últimos 14 años, en el marco científico y regulador impulsado por la UE desde el año 2000. Sin embargo, se analizarán las dificultades y oportunidades para impulsar la investigación traslacional en estas enfermedades.
Sigue la presentación en Youtube: https://www.youtube.com/watch?v=d4U4a8xFCzA&
Pharmacovigilance is the science of monitoring the safety of medicines. It plays a key role in identifying adverse drug reactions and preventing harm to patients. The goal of pharmacovigilance is to monitor drug safety, identify health risks, and prevent harm through careful tracking of side effects from clinical trials through a drug's entire lifecycle on the market. Major organizations like the FDA, EMEA, and WHO work to coordinate pharmacovigilance efforts internationally and protect public health.
Orphan Drugs and Haemophilia by Flora PeyvandiJordan Nedevski
1) Orphan drugs are developed for rare diseases that would otherwise be unprofitable to treat. Regulations in the US, EU, Japan, and Australia provide incentives like market exclusivity to stimulate orphan drug development.
2) New long-acting drugs for hemophilia, a rare bleeding disorder, could potentially qualify for orphan drug designation and the 10 years of market exclusivity in the EU. However, ensuring wide access and competition is important.
3) While long-acting hemophilia drugs differ in structure and mechanism, their market exclusivity status is unclear. The hemophilia community wants different treatment approaches and competition to best meet patient needs long-term.
This document discusses the challenges and strategies for successful orphan drug development. It notes that despite small patient populations, orphan drug development has grown significantly due to regulatory incentives. However, orphan drug development faces challenges including difficulties designing studies due to lack of disease information, problems recruiting small patient populations, and regulatory complexities. The document recommends three strategies for overcoming these challenges: 1) partnering with experienced CROs knowledgeable in rare diseases, 2) engaging key opinion leaders to help with sites and education, and 3) allowing flexibility in protocols and budgets to address unexpected changes common in rare disease studies. Overall the document outlines the benefits and hurdles of orphan drug development and provides guidance on navigating clinical and regulatory obstacles.
This document discusses treatments for rare diseases developed by Genzyme, including treatments for Pompe disease, Gaucher disease, and multiple sclerosis. It provides an overview of Genzyme's focus on rare diseases, marketed products, employees, and history of pioneering treatments for rare diseases. It also summarizes the challenges of developing treatments for rare diseases and orphan drugs, the regulatory pathways and incentives for such treatments, and Genzyme's manufacturing network and approach to working with patients.
‘Orphan drugs’ future growth potential for indian pharmaceutical marketNitin Patel
This document discusses orphan drugs and their potential in the Indian pharmaceutical market. It defines orphan drugs as those developed for rare diseases affecting less than 8% of the population. The US was the first to pass orphan drug legislation in 1983 to incentivize development of these drugs. Similar laws now exist in other countries and provide benefits like 7 years of market exclusivity. While initially developed for small populations, some orphan drugs like Rituxan have become very profitable blockbusters. The global orphan drug market was worth $50 billion in 2011 and is growing faster than other drug markets. Several Indian companies are now developing or manufacturing orphan drugs for rare diseases.
This document provides an overview of recent advances in HIV/AIDS treatment. It discusses how combination antiretroviral therapy pills have simplified treatment regimens. New drug classes such as entry inhibitors and integrase inhibitors have been developed that target different parts of the viral lifecycle. Studies have also shown benefits of starting antiretroviral treatment earlier, even before symptoms develop. Vaccine research continues in an effort to develop a preventive vaccine, with some studies showing a limited level of effectiveness.
Regulatory requirements on herbal drugs understading the global perspectivessuserd3ff07
This document discusses regulatory requirements for herbal drugs from a global perspective. It outlines challenges countries face in regulating herbal medicines, including assessing safety and efficacy, quality control, and monitoring adverse effects. Regulations vary significantly between countries and regions. Europe implemented strict regulations after an herbal supplement mix-up caused kidney failure in thousands of women. The US regulates herbal supplements as dietary supplements rather than drugs. Other countries discussed include India, Malaysia, Singapore, China, the Philippines, Nigeria, Saudi Arabia, Australia, Canada, and Japan. The conclusion emphasizes the need for standardized, strengthened global regulation of herbal medicines given increased use and reports of adverse effects.
Dr. Vikram Sharma discusses the history and development of policies and regulations related to orphan drugs and rare diseases. Key events include the establishment of the FDA's Office of Orphan Products Development in 1982 and the passing of the Orphan Drug Act in 1983 in the US. The document outlines incentives provided by various countries and regions to promote research and development of orphan drugs, and challenges that still remain in ensuring access and affordability of treatments for rare diseases.
This document discusses developing orphan drugs in Asia through collaboration between biotech companies and policymakers. It provides definitions of orphan drugs and rare diseases in various countries. Legislation has promoted orphan drug development by providing market exclusivity, reduced regulatory requirements, and reimbursement for treatment costs. Successful strategies include becoming the first mover, focusing on patients, collaborating with professional societies, and obtaining financial support. Challenges include small patient populations and ensuring treatment affordability and access. Case studies demonstrate approaches like compassionate use programs and conducting global clinical trials to facilitate regulatory approval.
A rare disease is a disease that affects a tiny percentage of the population. In other words, an orphan disease is a rare disease, which means that there is a shortage of a market to get support and resources for discovering treatments for it.
Virginia Llera - Cómo optimizar la investigación en Enfermedades RarasFundación Ramón Areces
La Doctora Virginia Llera, Virginia A. Llera ofreció una conferencia el 17/09/2014 en la Fundación Ramón Areces. Llera es la Fundadora de la primera organización de Enfermedades Raras y drogas huérfanas en Latino América y Caribe, GEISER, y Presidenta del Foro Internacional, ICORD (International Conference on Rare Diseases & Orphan Drugs). Su conferencia, titulada 'Optimizando los procesos de investigación en enfermedades raras y medicamentos huérfanos', tuvo lugar dentro del ciclo sobre patologías poco frecuentes organizado por Fundación Ramón Areces en colaboración con Vall d'Hebron Institute of Research, Barcelona.
Securing the Global Pharmaceutical Supply Chain against the Threat of Counter...Yasmin AbdelAziz
In 2012, counterfeit versions of the cancer drug
Avastin were found in 19 American treatment
centers. The impostor drug lacked the active
ingredient, rendering it virtually useless for
treatment purposes.
This document provides an introduction to pharmacovigilance. It defines pharmacovigilance as the science relating to detecting, assessing, understanding, and preventing adverse drug reactions. The document outlines the need for pharmacovigilance due to limitations of clinical trials, medication errors, and adverse drug reactions being a leading cause of death. It describes Egypt's pharmacovigilance center and important terms like adverse drug reactions, adverse events, and serious reports. Healthcare professionals, patients, and marketing authorization holders should report valid adverse events containing identifiable information to the pharmacovigilance center.
Similar to NEW POWER POINT PRESENTATION ON ORPHAN DISEASES AND DRUGS (20)
How to Make a Field Mandatory in Odoo 17Celine George
In Odoo, making a field required can be done through both Python code and XML views. When you set the required attribute to True in Python code, it makes the field required across all views where it's used. Conversely, when you set the required attribute in XML views, it makes the field required only in the context of that particular view.
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
This slide is special for master students (MIBS & MIFB) in UUM. Also useful for readers who are interested in the topic of contemporary Islamic banking.
The simplified electron and muon model, Oscillating Spacetime: The Foundation...RitikBhardwaj56
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
A review of the growth of the Israel Genealogy Research Association Database Collection for the last 12 months. Our collection is now passed the 3 million mark and still growing. See which archives have contributed the most. See the different types of records we have, and which years have had records added. You can also see what we have for the future.
it describes the bony anatomy including the femoral head , acetabulum, labrum . also discusses the capsule , ligaments . muscle that act on the hip joint and the range of motion are outlined. factors affecting hip joint stability and weight transmission through the joint are summarized.
Walmart Business+ and Spark Good for Nonprofits.pdfTechSoup
"Learn about all the ways Walmart supports nonprofit organizations.
You will hear from Liz Willett, the Head of Nonprofits, and hear about what Walmart is doing to help nonprofits, including Walmart Business and Spark Good. Walmart Business+ is a new offer for nonprofits that offers discounts and also streamlines nonprofits order and expense tracking, saving time and money.
The webinar may also give some examples on how nonprofits can best leverage Walmart Business+.
The event will cover the following::
Walmart Business + (https://business.walmart.com/plus) is a new shopping experience for nonprofits, schools, and local business customers that connects an exclusive online shopping experience to stores. Benefits include free delivery and shipping, a 'Spend Analytics” feature, special discounts, deals and tax-exempt shopping.
Special TechSoup offer for a free 180 days membership, and up to $150 in discounts on eligible orders.
Spark Good (walmart.com/sparkgood) is a charitable platform that enables nonprofits to receive donations directly from customers and associates.
Answers about how you can do more with Walmart!"
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
This presentation includes basic of PCOS their pathology and treatment and also Ayurveda correlation of PCOS and Ayurvedic line of treatment mentioned in classics.
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
2. ORPHAN DISEASES
An orphan disease is defined as a condition
that affects fewer than 200,000 people
nationwide. This includes diseases as
familiar as cystic fibrosis, Lou Gehrig's
disease, and Tourette's syndrome, and as
unfamiliar as Hamburger disease, Job
syndrome, and acromegaly, or "gigantism”.
A disease or disorder is defined as rare in Europe when it
affects fewer than 1 in 2000. A disease or disorder is defined
as rare in the USA when it affects fewer than 200,000
Americans or about 1 in 1500 Americans.
According to the definition by the World Health Organization
(WHO), an orphan disease is an illness or condition that occurs
from 0.65 to 1 case per 1000 population, with a prevalence from
6.5 to 10 cases per 10.000 residents.
3. Annually, approximately 250 new orphan diseases are identified
Despite the fact that orphan diseases affect a small portion of the
world population, it is estimated that over 55 million people suffer
from orphan diseases at the level of the United States (USA) and
European Union (EU).
In the USA there are about 25 million people who suffer from an
orphan disease, while at European level about 30 million people
are registered with orphan diseases, meaning that orphan
diseases affect 6% to 8% of the population at European level .
The large part of orphan diseases (about 50%) appear during
early childhood. Approximately 80% of the known orphan diseases
have been identified as genetic in nature affecting between 3%
and 4% of the newborns.
4. EXAMPLES OF RARE DISEASES
Gaucher disease
Gaucher disease is a rare genetic disorder
characterized by the deposition of
glucocerebroside in cells of the macrophage-
monocyte system. The disorder results from
the deficiency of the enzyme
glucocerebrosidase.The prevalence of
Gaucher disease is around 2 in 100 000.
Gaucher disease is the result of a buildup of
certain fatty substances in certain organs,
particularly your spleen and liver.
An enzyme that breaks down these fatty substances doesn't work
properly in people with Gaucher disease.Treatment often includes
enzyme replacement therapy.
This causes these organs to enlarge and can affect their function.
5. Von Hippel-Lindau (VHL)
Von Hippel-Lindau disease (VHL) is said to
affect one in 35,000 people. It is an extremely
rare genetic condition that is characterized
by the growth of tumors in different parts of
the body. Many of the tumors will grow
within the central nervous system and are
often benign, but are made of blood vessels.
Medically known as hemangioblastomas, these tumors can
start to grow in the retina, the brain, and the spinal cord.
Different tumors are also known to grow on the pancreas,
adrenal glands, and kidneys. If left untreated, the disease can
cause strokes, heart attacks, and cardiovascular disease.
6. Microcephaly
Microcephaly is a very rare condition that is
noticeable immediately at birth, and sometimes
even before. It affects 1 in every 666,666 in the
U.S. With microcephaly, the brain is unable to
develop properly, or in some cases ceases to
grow at all, while the baby is still in the womb.
Many believe that the disease is caused by
exposure to harmful substances while in the
womb, exposure to radiation, or genetic
problems.
The disease is usually paired with Down’s syndrome. Those
who have microcephaly are usually mentally retarded and will
have issues with hyperactivity, dwarfism, seizures, balance
issues, speech and motor problems, as well as others.
7. ORPHAN DRUGS
Orphan drugs are medicines or vaccines intended to treat, prevent or diagnose
a rare disease. Examples of rare diseases include genetic diseases, rare
cancers, infectious tropic diseases and degenerative diseases.
Type Detail Expected profits Available
medication
I Little / no
commercial benefit
Poor Inadequate
II Commercial
benefit
Good to excellent Inadequate
III For rare disease
that can currently
be treated
Variable Adequate
IV Unprofitable for a
common disease
Poor Inadequate
V Orphan for both
rare and common
diseases
Variable Variable
Categories of Orphan Drugs
9. ORPHAN DRUG REGULATION IN US AND EUROPE
ORPHAN DRUG REGULATION IN US
The legal status had been given to the orphan drugs in the USA
on 4 January 1983 with the passing of an act called the Orphan
Drug Act.
The Orphan Drug Act is passed to stimulate the development of
drugs and biological products for the treatment of rare diseases.
The ODA includes specific regulations that were developed to
promote R&D investment in orphan drugs. The ODA has
several parts but its main purpose is to reduce costs and
increase the returns to orphan drug production. The ODA
allows drug sponsors to obtain recommendations from the
FDA pertaining to the clinical and nonclinical trials of a drug
before its approval.
10. Additionally, the ODA allows the FDA to expedite orphan drug
designation approvals over other drugs, reducing the development
time. The ODA also established a grant program in which subsidies
are given to drug manufacturers, to a total of about $30,000,000
each fiscal year.This helps cover some of the costs of clinical trials.
This act delivers incentives to pharmaceutical companies to
develop drugs which are lifesaving and often essential for the
patients suffering from rare diseases but had a marginal
commercial profit on investment. The Orphan Drug Act is codified
in 21 CFR Part 316.
11. ORPHAN DRUG REGULATION IN EUROPE
In 2000, the European Union (EU) has enacted similar legislation,
Regulation(EC) No 141/2000, which refers to drugs developed to
treat rare diseases to as "orphan medicinal products". The EU's
legislation is administered by the Committee on Orphan Medicinal
Products of the European Medicines Agency (EMA).
The first step towards making regulations for orphan drugs in EU
was recognition of an emotion that patients suffering from rare
conditions should be entitled to the same quality of treatment as
other patients. This was recognized and protected in European law
with the European regulation 141/2000. Profitable incentives were
given in 141/2000 regulation to try to motivate the manufacturers
and researchers to develop the orphan medicinal products.
12. The regulation (EC) No. 141/2000 for orphan drugs was approved
on 16 December 1999 by the European Parliament and the
Council. The aim was to construct a Committee on Orphan
Medicinal Products (COMP) as a subunit of the European
Medicines Evaluation Agency (EMEA) which would boost the
biotechnological and pharmaceutical industry to discover,
develop and market orphan drugs.
The COMP consists of 28 members nominated by each the
European Member State; three members are nominated by the
European Commission and three agents of patient associations.
The Committee of Propriety Medicinal Products remains in
contact with COMP for scientific evaluation of medicinal products
and both are accountable for EMEA. The participation of patient
association’s agents of COMP has been very considerable in the
process of emerging new treatments for rare diseases in Europe.
13. ORPHAN DESIGNATION
“The orphan drug act(ODA) provides for granting special
status to a drug or biological product to treat a rare
disease or condition upon request of a sponsor.This status
is referred to as ORPHAN DESIGNATION or sometimes
orphan status.”
ORPHAN DRUG DESIGNATION IN US
The Orphan Drug Designation program provides orphan
status to drugs and biologics which are defined as those
intended for the safe and effective treatment, diagnosis
or prevention of rare diseases/disorders that affect fewer
than 200,000 people in the U.S., or that affect more than
200,000 persons but are not expected to recover the costs
of developing and marketing a treatment drug.
14. The OOPD(office of orphan product development) is answerable
for assessing, awarding, and watching the progress of orphan drug
grants. The ODA make available for granting special status, orphan
drug designation, of a product to treat a rare disease or condition
upon request of a sponsor.
Orphan Drug Status
This may be entitled to a drug if it meets the following criteria:
• A drug is not approved earlier
• An approved drug with new orphan indication
• A drug proved clinically superiority over previously approved drug
of same category.
15. ORPHAN DRUG DESIGNATION IN THE EUROPE
Orphan designation in Europe is based on the criteria laid down in
Regulation (EC) No 141/2000. Designation is free of charge, and may
be obtained at any stage of development before an application for
marketing authorization is made, provided proper scientific justification
of the intended use is submitted.
EMA's role in orphan designation
The Agency is responsible for reviewing applications from sponsors
for orphan designation.To qualify for orphan designation, a medicine
must meet a number of criteria:
•the prevalence of the condition in the EU must not be more than 5 in
10,000 or it must be unlikely that marketing of the medicine would
generate sufficient returns to justify the investment needed for its
development;
16. •no satisfactory method of diagnosis, prevention or treatment of the
condition concerned can be authorized or if such a method exists, the
medicine must be of significant benefit to those affected by the
condition.
Applications for orphan designation are examined by the
EMA's Committee for Orphan Medicinal Products (COMP), using the
network of experts that the Committee has built up. The evaluation
process takes a maximum of 90 days from validation.
•it must be intended for the treatment, prevention or diagnosis of a
disease that is life-threatening or chronically debilitating;
17. MARKET EXCLUSIVITY OF ORPHAN DRUGS
Marketing Exclusivity is exclusive marketing rights granted by the
FDA upon approval of a drug and can run concurrently.
ORPHAN DRUG EXCLUSIVITY IN US
•The Orphan Drug Act provides drug manufacturers with ‘7’ years of
market exclusivity period after FDA’s approval of the drug, as well as
research grants and tax credits for each new orphan drug developed.
•If a product is granted orphan drug exclusivity, FDA may not
approve (but may accept) applications for generic or second
innovator products that contain the same active ingredient and are
labeled for the same orphan indication. However, FDA may accept
and approve applications for drugs having the same active moiety,
for a different indication.
18. ORPHAN DRUG EXCLUSIVITY IN EUROPE
The benefits of orphan drug designation in the EU are vast. If
marketing authorization is granted pursuant to the EU’s centralized
procedure or by all Member States, the Community and the Member
States may not accept or grant for ‘10’ years, a new marketing
authorization or accept an application to extend an existing marketing
authorization, for the same therapeutic indication as an orphan drug.
Although market exclusivity for orphan drugs is generally granted
for a period of 10 years, it may be extended to 12 years for pediatric
products, or may be reduced to six years if, at the end of the fifth
year of exclusivity, the drug no longer satisfies the original
designation criteria.
19. INCENTIVES FOR ORPHAN DRUG LEGISLATION IN US
AND EUROPE
The Orphan Drug Act (1983) established
several incentives to encourage the
development of orphan drugs (ODs) to treat
rare diseases and conditions. This study
analyzed the characteristics of OD
designations, approvals, sponsors, and
evaluated the effective patent and market
exclusivity life of orphan new molecular
entities (NMEs) approved in the US
between 1983 and 2007.
21. INCENTIVES FOR ORPHAN DRUG IN EUROPE
• Market exclusivity
For 10 years after the granting of a marketing authorization (approval for
sale), orphan medicinal products benefit from market exclusivity in the
EU. During that period, directly competitive similar products cannot
normally be placed on the market.
• Protocol assistance
The Agency can provide scientific advice to optimize development and
guidance on preparing a dossier that will meet European regulatory
requirements.
• Fee reductions
A special fund from the European Commission, agreed annually by the
European Parliament, is used by the Agency to grant fee reductions.
• EU-funded research
Sponsors developing orphan medicinal products may be eligible for
grants from EU and Member State programmes and initiatives
supporting research and development, including the Commission's
framework programme.